Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden

International Journal of Cardiology

Volumn 175, Issue 1, 2014, Pages 55-61

  Thorvaldsen, Tonje ^a   Benson, Lina ^b   Hagerman, Inger ^a   Dahlström, Ulf ^c   Edner, Magnus ^a   Lund, Lars H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Guidelines; Health care utilization; Heart failure; Indications; Inotropes; levosimendan

Indexed keywords

INOTROPIC AGENT; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CLINICAL FEATURE; CONTROLLED STUDY; DEFIBRILLATION; DESCRIPTIVE RESEARCH; DISEASE REGISTRY; DRUG CHOICE; DRUG INDICATION; DRUG USE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN; TREATMENT PLANNING; VENTRICULAR ASSIST DEVICE; CLINICAL TRIAL; DRUG ADMINISTRATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; REGISTER; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOLOGY; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INTERNAL MEDICINE; MALE; MIDDLE AGED; PYRIDAZINES; REGISTRIES; SURVIVAL RATE; SWEDEN;

EID: 84902539168     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.243     Document Type: Article

References (27)

1. M. Jessup, and S. Brozena Heart failure N Engl J Med 348 2003 2007 2018
2. A.P. Maggioni, U. Dahlstrom, and G. Filippatos et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot) Eur J Heart Fail 12 2010 1076 1084
3. A.P. Maggioni, U. Dahlstrom, and G. Filippatos et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) Eur J Heart Fail 15 2013 808 817
4. M.S. Nieminen, D. Brutsaert, and K. Dickstein et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2006 2725 2736
5. M.S. Cuffe, R.M. Califf, and K.F. Adams Jr. et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547
6. W.T. Abraham, K.F. Adams, and G.C. Fonarow et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 2005 57 64
7. A.D. Michaels, B. McKeown, and M. Kostal et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake Circulation 111 2005 1504 1509
8. F. Follath, J.G. Cleland, and H. Just et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 2002 196 202
9. V.S. Moiseyev, P. Poder, and N. Andrejevs et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
10. A. Mebazaa, M.S. Nieminen, and M. Packer et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 2007 1883 1891
11. M. Packer, W. Colucci, and L. Fisher et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure JACC Heart Fail 1 2013 103 111
12. J.J. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
13. L.W. Miller Left ventricular assist devices are underutilized Circulation 123 2011 1552 1558 discussion 8
14. C.M. O'Connor, W.A. Gattis, and B.F. Uretsky et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 1999 78 86
15. C. Rapezzi, G. Bracchetti, A. Branzi, and B. Magnani The case against outpatient parenteral inotropic therapy for advanced heart failure J Heart Lung Transplant 19 2000 S58 S63
16. J. Lilleberg, M. Laine, T. Palkama, M. Kivikko, P. Pohjanjousi, and M. Kupari Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure Eur J Heart Fail 9 2007 75 82
17. S. Silvetti, T. Greco, and A.L. Di Prima et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials Clin Res Cardiol 2013 [epub ahead of print]
18. J. Altenberger, J.T. Parissis, H. Ulmer, and G. Poelzl Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study) Eur J Heart Fail 12 2010 186 192
19. L.H. Lund, J. Matthews, and K. Aaronson Patient selection for left ventricular assist devices Eur J Heart Fail 12 2010 516 520
20. A. Jonsson, M. Edner, U. Alehagen, and U. Dahlstrom Heart failure registry: a valuable tool for improving the management of patients with heart failure Eur J Heart Fail 12 2010 25 31
21. L.H. Lund, L. Benson, U. Dahlstrom, and M. Edner Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction JAMA 308 2012 2108 2117
22. J.N. Nanas, P. Papazoglou, and E.P. Tsagalou et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone Am J Cardiol 95 2005 768 771
23. S. Mavrogeni, G. Giamouzis, and E. Papadopoulou et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure J Card Fail 13 2007 556 559
24. M.J. Bonios, J.V. Terrovitis, and S.G. Drakos et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure Int J Cardiol 159 2012 225 229
25. G. Malfatto, F. Della Rosa, and A. Villani et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival J Cardiovasc Pharmacol 60 2012 450 455
26. R. Berger, D. Moertl, and M. Huelsmann et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure Eur J Heart Fail 9 2007 202 208
27. M.S. Nieminen, J. Altenberger, and T. Ben-Gal et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. Int J Cardiol 174 2 2014 Apr 18 360 367